The current valuation score of Enlivex Therapeutics Ltd is 9.94, ranking 3 out of 387 in the Biotechnology & Medical Research industry. Its current P/E ratio is 0.06, which is 368.66% below the recent high of 0.27 and 5498.63% above the recent low of -3.15.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.